SolarWinds , a leading provider of simple, powerful, secure observability and IT management software, unveils the next phase of enhancements to the SolarWinds Partner Program. These updates focus on ...

Hello, and welcome to the WEX fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

First Jointly Developed AI Agent Helps Customers Maximize Cisco Investments and Boosts Productivity   News Summary: Powerful Partnership: The first of several AI agents being developed by Cisco with ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

In the Phase 2 open-label Oral Anaphylm Symptom Intervention Study ("OASIS”) study, adults with Oral Allergy Syndrome (n=36) received Anaphylm under different conditions, including single and repeat ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 22, 2025 /PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The first-ever edition of the UEFA Champions League's knockout phase playoffs begins this week when several European heavyweights will compete for a spot in the round of 16. The headlining act of ...

Satellos Bioscience has concluded the enrolment of subjects for all four multiple-ascending dose (MAD) cohorts for the Phase I trial of the oral small-molecule drug SAT-3247. The drug is being ...